IP Library Granted Patent US 12680111
Granted Patent B2
US 12680111 · App. 18/281,703 · Granted Jul 14, 2026

Synthetic promoters for gene therapy and protein expression

Inventors: Yang Wang (Wellesley, MA); Mark S. Klempner (Boston, MA); Monir Ejemel (Medfield, MA); Qi Li (Westwood, MA); Zuoshang Xu (Wellesley, MA)
Assignee: University of Massachusetts
C12N15/86A61K48/0066C12N2750/14143C12N2750/14171C12N2830/15
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12680111
App. No.
18/281,703
Granted
Jul 14, 2026
Kind
B2
Abstract

The invention provides synthetic promoters and methods of using the same.

Claims (31)

1 . A promoter-associated intronic sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 1.

2 . A promoter-associated intronic sequence comprising the nucleic acid sequence of SEQ ID NO: 1.

3 . A polynucleotide comprising the promoter-associated intronic sequence of claim 1 and a nucleic acid sequence encoding an enhancer sequence.

4 . A promoter sequence comprising a nucleic acid sequence comprising an enhancer sequence, a nucleic acid sequence comprising a core promoter sequence, and the promoter-associated intronic sequence of claim 1 .

5 . The promoter sequence of claim 4 , wherein the nucleic acid sequence comprising the core promoter sequence is:

(a) operably linked at its 5′ end to the 3′ end of the enhancer sequence; and

(b) operably linked at its 3′ end to the 5′ end of the promoter-associated intronic sequence.

6 . The promoter sequence of claim 4 , wherein:

(i) the enhancer sequence is a CMV enhancer sequence; and/or

(ii) the core promoter sequence is a chicken β-actin core promoter sequence.

7 . The promoter sequence of claim 6 , wherein:

(i) the CMV enhancer sequence comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 3; and/or

(ii) the chicken β-actin core promoter sequence comprises a nucleic acid sequence having at least 95% identity to SEQ ID NO: 4.

8 . The promoter sequence of claim 4 , wherein the promoter sequence is operably linked to a target nucleic acid sequence.

9 . The promoter sequence of claim 8 , wherein the target nucleic acid sequence encodes an RNA.

10 . The promoter sequence of claim 9 , wherein:

(a) the RNA is a miRNA, an siRNA, a shRNA, or a guide RNA (gRNA); and/or

(b) the target nucleic acid sequence encodes an mRNA that is translated to a protein or polypeptide.

11 . A promoter sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 6.

12 . A delivery vehicle comprising the polynucleotide of claim 3 .

13 . The delivery vehicle of claim 12 , wherein the delivery vehicle is a viral vector, an adeno-associated viral (AAV) vector, or a lentiviral vector.

14 . A host cell comprising the polynucleotide of claim 3 .

15 . A method of producing an RNA, protein, or polypeptide in a cell, the method comprising:

(a) providing a polynucleotide comprising a promoter sequence of claim 4 and a target nucleic acid sequence encoding the RNA, protein, or polypeptide, wherein the promoter sequence is operably linked to the target nucleic acid sequence;

(b) introducing the polynucleotide into a host cell;

(c) exposing the host cell comprising the polynucleotide to conditions suitable for expression of the RNA, protein, or polypeptide, thereby producing the RNA, protein, or polypeptide; and

(d) recovering the RNA, protein, or polypeptide from the host cell or host cell culture medium.

16 . A method of expressing an RNA, protein, or polypeptide in a subject, the method comprising administering to the subject an effective amount of a delivery vehicle comprising a polynucleotide comprising a promoter sequence of claim 4 and a target nucleic acid sequence encoding the RNA, protein, or polypeptide, wherein the promoter sequence is operably linked to the target nucleic acid sequence.

17 . The method of claim 16 , wherein the delivery vehicle is a vector.

18 . The method of claim 17 , wherein the vector is a viral vector, an AAV vector, a single chain rAAV vector, a self-complementary AAV, or a lentiviral vector.

19 . A method of inducing an immune response in a subject, the method comprising administering to the subject an effective amount of a delivery vehicle comprising a polynucleotide comprising a promoter sequence of claim 4 and a target nucleic acid sequence encoding an RNA, protein, or polypeptide, wherein the promoter sequence is operably linked to the target nucleic acid sequence, and wherein expression of the RNA, protein, or polypeptide elicits an immune response.